A retrospective cohort study assessing healthcare resource utilisation and direct medical costs in patients with COPD receiving ICS/LABA Therapy in England
Latest Information Update: 30 Aug 2023
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Budesonide/formoterol (Primary) ; Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary) ; Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 11 Jan 2022 New trial record
- 03 Dec 2021 Results presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research